Net Income

Avalon GloboCare regains Nasdaq compliance, but its future is being reshaped by a bold AI launch and a transformative merger that questions its identity.

Subaru and Operation Warm expand their partnership to provide essentials to 140,000 children, addressing a stark, record-breaking rise in youth homelessness.

FirmTech is taking its AI-powered sexual wellness wearables worldwide, betting on data to revolutionize men's health. But can it navigate global privacy hurdles?

Orrstown Financial Advisors is opening a dedicated 4,000 sq. ft. office, signaling a strategic push to enhance client service in a growing regional market.

Manas AI gains unique access to Schrödinger's physics platform, uniting top minds and tech to slash drug development timelines. Is this the future?

The fintech firm completes its transformation into a diversified industrial compounder, creating GPGI Inc. under the leadership of veteran CEO Dave Cote.

Progyny signals better-than-expected 2025 results on robust member engagement, sparking analyst upgrades and sending its stock soaring ahead of a key conference.

New 2025 data reveals an AI platform is slashing costs, improving chronic disease outcomes, and closing health equity gaps for hundreds of clinicians.

The wellness firm secured a cash infusion by repricing options, a move that provides vital funds for its Zola brand but raises questions about dilution.

Tech consultancy Hylaine hires veteran exec Doug Hautop as President to lead an aggressive plan to scale, targeting Fortune 1000 enterprise clients.

Petco is refinancing $1.5B in debt to extend maturities while reaffirming its financial outlook. Is this a sign of strength or underlying strain?

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

Retailers are losing billions to refund abuse, but new AI tools can spot fraud in real time, protecting revenue without punishing your best customers.

For the 24th straight year, nurses top Gallup's ethics poll, but this enduring trust masks a profession in crisis, battling burnout and staff shortages.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

Biomea Fusion launches a high-stakes 2026 plan, advancing a novel diabetes drug to restore insulin cells and an oral pill to rival obesity giants.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

Interim data suggests LX2020 is well-tolerated and may reduce dangerous arrhythmias by targeting the root cause of PKP2-associated cardiomyopathy.

Backed by Purolator, a massive network expansion by Williams Pharmalogistics aims to reshape Canada's temperature-controlled medical delivery landscape.